3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Follicular
5
Lymphoma
4
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, B-Cell
3
Lymphoma, Large B-Cell, Diffuse
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Diseases
1
Graft vs Host Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Bronchiolitis Obliterans Syndrome
1
Anemia
1
Interventions
duvelisib
1
Rituximab
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA